What question did this study set out to answer?

This study aims to assess the effects of dapagliflozin on kidney function and albuminuria in children with chronic kidney disease.

Dapagliflozin preserves kidney function and reduces albuminuria in children with chronic kidney disease

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates dapagliflozin's effects on kidney function and albuminuria in children, indicating positive outcomes.

This study aims to assess the effects of dapagliflozin on kidney function and albuminuria in children with chronic kidney disease.
Multicenter, randomized, open-label, endpoint-blinded controlled trial involving 114 children with CKD stages 1-4.
Participants were assigned to receive either dapagliflozin plus standard care or standard care alone for 4 months.
Primary outcomes included changes in estimated glomerular filtration rate and urine albumin-to-creatinine ratio.
Dapagliflozin group saw an increase in eGFR by +2.1 mL/min/1.73 m² while control group declined by -4.2 mL/min/1.73 m², between-group difference of 6.3 mL/min/1.73 m² (95% CI 2.1-10.5; p=0.004).
UACR decreased by -19.8 mg/g in the dapagliflozin group compared to control (95% CI: -21.9 to -18.6; p=0.002).
No serious adverse events were reported.

Assadi et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark